Janux Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Janux Therapeutics
JANX Stock  USD 23.56  0.46  1.92%   
Janux Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Janux Therapeutics' valuation are provided below:
Gross Profit
-70 M
Market Capitalization
1.4 B
Enterprise Value Revenue
43.1269
Revenue
9.3 M
Earnings Share
(1.36)
We have found one hundred twenty available fundamental trends for Janux Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Janux Therapeutics regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 3 B in 2025. Enterprise Value is likely to rise to about 2.6 B in 2025

Janux Therapeutics Total Revenue

5.74 Million

Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 31.3 M, Depreciation And Amortization of 2.4 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 285, Dividend Yield of 0.0 or PTB Ratio of 2.95. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Janux Stock
Check out the analysis of Janux Therapeutics Correlation against competitors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Janux Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.1 B207.7 M
Slightly volatile
Short and Long Term Debt Total17 M23 M8.1 M
Slightly volatile
Other Current Liabilities5.9 M11.7 M2.6 M
Slightly volatile
Total Current Liabilities12.4 M17.5 M7.6 M
Slightly volatile
Property Plant And Equipment Net15.2 M24.1 M6.2 M
Slightly volatile
Accounts Payable2.2 M4 M1 M
Slightly volatile
Cash452.1 M430.6 M62.7 M
Slightly volatile
Non Current Assets Total17.2 M27.9 M6.9 M
Slightly volatile
Cash And Short Term Investments1.1 B1 B197.6 M
Slightly volatile
Common Stock Total Equity50.7 K48.3 K14.7 K
Slightly volatile
Common Stock Shares Outstanding48.3 M53.8 M42.9 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.1 B207.7 M
Slightly volatile
Non Current Liabilities Total19 M21.3 M9.9 M
Slightly volatile
Other Stockholder Equity1.3 B1.3 B251.4 M
Slightly volatile
Total Liabilities31.4 M38.7 M17.5 M
Slightly volatile
Property Plant And Equipment Gross16.7 M29.1 M6.7 M
Slightly volatile
Short and Long Term Debt3.2 M3.6 M3.9 M
Slightly volatile
Total Current Assets1.1 B1 B200 M
Slightly volatile
Capital Stock34.8 K59 K14.6 K
Slightly volatile
Short Term Debt1.3 M1.7 M3 M
Slightly volatile
Common Stock34.8 K59 K14.6 K
Slightly volatile
Property Plant Equipment8.6 M8.1 M2.1 M
Slightly volatile
Other Liabilities2.4 M2 M4.8 M
Slightly volatile
Current Deferred Revenue2.8 M1.5 M2.4 M
Slightly volatile
Other Current Assets4 M3.1 M1.7 M
Slightly volatile
Other Assets1.9 M2.5 M1.5 M
Slightly volatile
Capital Surpluse465.7 M497.6 M424.8 M
Slightly volatile
Non Current Liabilities Other32.3 M30.8 M7.8 M
Slightly volatile

Janux Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.4 M2.2 M474.4 K
Slightly volatile
Interest Expense4.9 M4.6 M1.3 M
Slightly volatile
Selling General Administrative43.1 M41 M9.5 M
Slightly volatile
Other Operating Expenses57.1 M109.4 M25.2 M
Slightly volatile
Research Development38.3 M68.4 M17.1 M
Slightly volatile
Cost Of Revenue2 M2.1 M7.4 M
Slightly volatile
Total Operating Expenses57.1 M109.4 M25.2 M
Slightly volatile
Reconciled Depreciation2.2 M2.1 M442.3 K
Slightly volatile
Non Operating Income Net Other2.4 M4.6 M1.1 M
Slightly volatile

Janux Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings25.6 M26.9 M20.2 M
Slightly volatile
Stock Based Compensation34.7 M33 M7 M
Slightly volatile
Begin Period Cash Flow21.6 M20 M9 M
Slightly volatile
Other Cashflows From Financing Activities29.7 M15 M18 M
Slightly volatile
Depreciation2.2 M2.1 M450.3 K
Slightly volatile
Capital Expenditures341.1 K359 K1.7 M
Very volatile
Total Cash From Financing Activities748.9 M713.2 M122.5 M
Slightly volatile
End Period Cash Flow453 M431.4 M63 M
Slightly volatile
Change To Netincome20.8 M19.8 M5.4 M
Slightly volatile
Change To Liabilities3.8 M6.5 M1.8 M
Slightly volatile
Change To Inventory663.3 K955.6 K514.8 K
Slightly volatile
Sale Purchase Of Stock163.3 M183.8 M200.3 M
Slightly volatile
Change Receivables6.4 M7.2 M7.8 M
Slightly volatile
Cash And Cash Equivalents Changes17.8 M14.3 M25.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio285272210
Pretty Stable
Days Sales Outstanding148167182
Slightly volatile
Stock Based Compensation To Revenue1.93.11862.0181
Slightly volatile
Capex To Depreciation0.170.174310.3959
Slightly volatile
EV To Sales245233198
Slightly volatile
Payables Turnover0.760.730.1867
Slightly volatile
Sales General And Administrative To Revenue2.53.87672.8922
Pretty Stable
Research And Ddevelopement To Revenue7.346.4597.0854
Slightly volatile
Capex To Revenue0.03220.03390.3708
Slightly volatile
Cash Per Share20.0319.07254.0151
Slightly volatile
Days Payables Outstanding49452011.5 K
Slightly volatile
Income Quality0.790.6350.8561
Slightly volatile
Current Ratio62.1759.205312.7653
Slightly volatile
Receivables Turnover1.581.771.9311
Slightly volatile
Capex Per Share0.00630.00670.0401
Very volatile
Revenue Per Share0.140.1970.1117
Slightly volatile
Interest Debt Per Share0.240.42840.185
Slightly volatile
Debt To Assets0.02060.02173.693
Slightly volatile
Days Of Payables Outstanding49452011.5 K
Slightly volatile
Ebt Per Ebit1.080.6981.033
Slightly volatile
Long Term Debt To Capitalization0.05690.0640.0697
Slightly volatile
Quick Ratio62.1759.205312.7689
Slightly volatile
Net Income Per E B T1.010.991.0044
Slightly volatile
Cash Ratio25.924.66383.8632
Slightly volatile
Days Of Sales Outstanding148167182
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.00821.0889
Very volatile
Fixed Asset Turnover0.420.43841.7982
Slightly volatile
Debt Ratio0.02060.02173.693
Slightly volatile
Price Sales Ratio285272210
Pretty Stable
Asset Turnover0.01770.010.0117
Slightly volatile
Gross Profit Margin0.950.80540.9402
Slightly volatile

Janux Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3 B2.9 B1.2 B
Slightly volatile
Enterprise Value2.6 B2.5 B1.1 B
Slightly volatile

Janux Fundamental Market Drivers

Cash And Short Term Investments1 B

Janux Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.5 M2.8 M
Total Revenue10.6 M5.7 M
Cost Of Revenue2.1 M2 M
Stock Based Compensation To Revenue 3.12  1.90 
Sales General And Administrative To Revenue 3.88  2.50 
Research And Ddevelopement To Revenue 6.46  7.34 
Capex To Revenue 0.03  0.03 
Revenue Per Share 0.20  0.14 
Ebit Per Revenue(9.34)(9.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
USOICredit Suisse X Links
ULTYTidal Trust II
CONYYieldMax N Option

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY